Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:9513 |
Name | plasma cell leukemia |
Definition | A plasma cell neoplasm that is characterized by the presence of a circulating clonal plasma cell count that exceeds 2x10^9/L or is 20% of the leukocyte differential count. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma non-Hodgkin lymphoma B-cell lymphoma mature B-cell neoplasm plasma cell neoplasm plasma cell leukemia |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03441958 | Phase Ib/II | Cyclophosphamide + ECT-001 cord blood cells + Fludarabine + Mycophenolate mofetil + Tacrolimus | ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma | Active, not recruiting | CAN | 0 |
NCT05208307 | Phase II | belantamab mafodotin-blmf + Dexamethasone + Pomalidomide | Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma | Recruiting | USA | 0 |
NCT05823571 | Phase I | Itacitinib | Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients | Recruiting | USA | 0 |
NCT06066359 | Phase Ib/II | Cyclophosphamide + Fludarabine + NY-ESO-1 TCR/IL-15 NK | Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma | Recruiting | USA | 0 |
NCT06517017 | Phase II | Dexamethasone + Isatuximab + Lenalidomide | Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma (UltraFrailMM) | Not yet recruiting | USA | 0 |
NCT06636552 | Phase II | Daratumumab Bortezomib + Cyclophosphamide + Daratumumab + Dexamethasone | An Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of Alternating Bortezomib-Based Regimens in Combination With DaratUMumab Followed by Maintenance With Daratumumab in the Frontline Setting of Primary Plasma CEll L (EUMELEIA) | Recruiting | GRC | 0 |